We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00531921
Recruitment Status : Completed
First Posted : September 19, 2007
Last Update Posted : June 4, 2013
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
Activity of genes in donor tissues that are involved in inflammation are thought to be involved with early organ dysfunction, increased immune responses in transplant recipients, and organ rejection. The purpose of this study is to determine the relationship between genetic expression in donor and recipient tissue with transplant survival. Participants in this study will have received heart, lung, liver, or kidney transplants.

Condition or disease
Heart Transplantation Kidney Transplantation Liver Transplantation Lung Transplantation

Detailed Description:

Inflammation and injuries to transplanted organs during the immediate post-operative period may be linked to early organ dysfunction and higher rates of transplant rejection in the recipient. Currently, mRNA expression of proinflammatory genes in donor tissues is thought to be a risk factor for early organ transplant dysfunction, increased expression of the recipients cell-mediated immunity genes, and organ rejection. The purpose of this study is to test the association between proinflammatory mRNA expression in donor samples and subsequent development of early organ dysfunction in kidney, lung, and liver transplant recipients. This study will also test the effects of proinflammatory mediators expressed in the transplanted organ pre- and post-reperfusion on organ rejection and genes expressed in cell mediated immune responses. This will be achieved by identifying the proinflammatory immune responses and their mechanisms.

This study will consist of up to 11 study visits over a period of 2 years. The baseline visit will occur 24 hours prior to organ transplantation. Follow-up visits will occur daily for Days 1 to 3 (for lung transplant recipients only) and on Day 7, Week 6, and Months 3, 6, 9, 12, 18, and 24 post-transplant. At the baseline visit, a physical exam, medical history, demographics, vital signs measurements, blood collection, and collection of donor tissue sample will occur. For most or all other study visits, medication and adverse events tracking and blood collection will occur. Depending on the transplant type, participants will undergo the following procedures:

  • Heart: Participants will undergo a heart biopsy that is part of standard clinical care following a heart transplant. An echocardiogram and an electrocardiogram will occur at most visits.
  • Kidney: Renal biopsies will be performed 1 hour after reperfusion at the time of surgery. Urine collection will occur at most visits.
  • Liver: Liver biopsies will be performed at the time of procurement and within 1 hour of reperfusion.
  • Lung: Participants will undergo bronchoalveolar lavage that is part of standard clinical care following a lung transplant. A chest x-ray, an arterial blood gas test, a pulmonary function test, and 6-minute walking test will occur at some visits.

Layout table for study information
Study Type : Observational
Actual Enrollment : 313 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Correlation of Donor Proinflammatory mRNA Profiles With Early Outcomes of Thoracic and Abdominal Transplantation
Study Start Date : September 2007
Actual Primary Completion Date : August 2011
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Organ Donation

Group/Cohort
Kidney transplants
patients from 5 specific sites
Liver transplants
patients from 5 specific sites
Heart transplants
patients from 5 specific sites
Lung transplants
patients from 5 specific sites



Primary Outcome Measures :
  1. Association between proinflammatory mRNA expression in donor samples and subsequent development of early organ dysfunction in the immediate period following transplantation [ Time Frame: Within first 7 days after transplant ]
  2. Association of mRNA expression of proinflammatory mediatros in the transplanted organ in the immediate pre and post-reperfusion period with subsequent incidence of acute rejection and expression of genes involved in cell mediated immunity [ Time Frame: 12 months after transplant ]

Biospecimen Retention:   Samples With DNA
Blood and tissue samples to evaluate the heart, kidney, liver, and lung


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Transplant patients evaluated for the association between proinflammatory mRNA expression from donor samples and subsequent development of early organ dysfunction
Criteria

Inclusion Criteria for all participants:

  • Received single lung, heart, kidney, or liver transplant
  • Specimens of donor tissues have been collected
  • Parent or guardian willing to provide informed consent, if applicable

Inclusion Criteria for Kidney or Liver Transplant Participants:

  • 70 years old or younger

Inclusion Criteria for Heart or Lung Transplant Participants:

  • Between 16 and 70 years old

Exclusion Criteria for All Participants:

  • Previous solid organ transplant
  • Need for combined organ transplant
  • HIV or hepatitis C virus infection
  • Recipient of an organ from a hepatitis C virus-infected donor
  • Clinical evidence of systemic bacterial infection in the recipient at the time of transplantation
  • Living donor transplant recipient of either a kidney, liver, or lung

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00531921


Locations
Layout table for location information
United States, Illinois
Northwestern Memorial Hospital (kidney and liver)
Chicago, Illinois, United States, 60611
United States, New York
Cornell University Medical College (kidney)
Ithaca, New York, United States, 14850
Columbia University (lung and liver)
New York, New York, United States, 10032
United States, Pennsylvania
University of Pennsylvania (heart, kidney, liver, lung)
Philadelphia, Pennsylvania, United States, 19104
United States, Wisconsin
University of Wisconsin (heart and lung)
Madison, Wisconsin, United States, 53706
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Principal Investigator: Abraham Shaked, MD, PhD University of Pennsylvania Medical Center
Additional Information:
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT00531921    
Other Study ID Numbers: DAIT CTOT-03
First Posted: September 19, 2007    Key Record Dates
Last Update Posted: June 4, 2013
Last Verified: June 2013
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Heart Diseases
Kidney Diseases
Liver Diseases
Liver Failure
Lung Diseases
Transplant
Transplantation, Homologous
Rejection
Kidney Failure